Obesity and fertility: the role of nutrition and pharmacotherapy options
Abstract
This article examines obesity as a chronic metabolic disease with a multifactorial etiology, involving a significant dietary component and epigenetic developmental mechanisms. Particular attention is paid to gender differences regarding pathogenesis, clinical manifestations, and treatment response, as well as the role of chronic inflammation (meta-inflammation) in the development of insulin resistance and metabolic disorders. The impact of various dietary patterns and specific nutrients, such as excess saturated and trans fatty acids, high-glycemic-index foods, advanced glycation end-products, and caffeine, on reproductive function is analyzed. The pathogenetic role of the "Western diet" in the development of ovarian dysfunction, hyperandrogenism, and reduced gamete quality is substantiated. Current data on the pharmacotherapy of obesity during the preconception period are presented, including GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide). The direct and indirect mechanisms of their influence on fertility, safety issues, and discontinuation timelines prior to conception are discussed. The article concludes by emphasizing the need for an interdisciplinary approach and personalized management strategies for patients of reproductive age with obesity.